It is worth remembering that PathAI also offers image management in addition to that image analysis. You cannot compare prices directly one-to-one.
4 Likes
What often bothers me about these Finnish medtech and pharma companies is that you canât find a single professional investor among the owners who truly understands the industry.
Back in the day, Revenio gained a lot of credibility when the Danes openly bought a large stake. In Sweden and other countries with longer traditions in the sector, there is often a specialized pharma VC firm in the background that has conducted proper DD (due diligence) based on non-public information and science before the IPO.
Aiforia seems like a more credible company than Nanoform or Nightingale, but it still lacks that quality seal from a professional investor. Or have I missed something?
5 Likes
The Board of Directors is probably the most important factor here, and it naturally reflects the structure of the ownership base.
Now we are talking about a completely different matter.
In VC rounds conducted before listing, a team that has deeply familiarized itself with the sector and seen hundreds of cases, assisted by scientific advisors, performs proper DD (Due Diligence) on the company, the competitive landscape, and the technology. Even if that analysis becomes outdated over the years, its existence indicates that the case made sense at least at some point.
Unfortunately, the best cases do not end up on the stock exchange but are sold via trade sale to competitors or large medtech firms.
Another possibility is that a specialist fund in the field enters the listed company either in the IPO, through a placement, or by buying directly from the market. There donât seem to be many such funds in Finland.
1 Like
A comment on the ongoing consolidation regarding the latest deals.
From Aiforiaâs perspective, the post is acknowledged by Gary Grisholm, a US sales reinforcement who moved from competitor Ibex Digital Pathology to Aiforia last year. LinkedIn is responsible for any translation errors.
Path AI was indeed a private company, so no official price could be seen on the stock exchange. Money has been poured in US-style, between 250-500 MUSD according to various sources. Thus, investors get a 2-4x return at best.
At the current valuations of Finol (the little brother of Hesuli/Helsinki), major owners aiming for an exit will likely do nothing but listen to offers with a smirk, if any come; there are undoubtedly always observers in companies that are interesting targets for integration. Aiforia has a growing portfolio of competitive AI models and tools for model development. The economic turnaround will, at the latest, trigger increased interest, when the time comes.
Path AI has a slightly different focus than Aiforia. Aiforia also collaborates with pharma, but surprisingly, the clinical models compete well, at least in Europe, even though we are playing with âpocket changeâ here in comparison.
The off-the-shelf models field (from Katieâs post, she is worth following).
There is still plenty to consolidate. Who is (was before Path AI + Roche) number one? Those at the top are most likely to hold their positions; no one wants a patchwork quilt of tools and suppliers.
15 Likes
Another post by Katie Maloney regarding the fragmented nature (patchwork) of digital pathology.
There is still room for consolidation even after this latest deal; Aiforia is mentioned as a âPlatform leaderâ.
19 Likes
This deal between Roche and PathAI came at a good time for Aiforia as well. I wonder if the board will rush a share issue through right after the extraordinary general meeting? At least they would get a better valuation than they would have 3 months ago 
By the way, how long is the so-called âclosed periodâ for the insiders regarding share purchases to avoid accusations of insider trading? Aiforia probably doesnât have any deals brewing just yet, since the insiders were still on the buying side at the end of March.
1 Like
I donât think thereâs a huge rush quite yet; thereâs a new clinical model coming out by the summer, for instance, and perhaps new customer agreements as well. It might be worth holding off on the offering for a moment.
4 Likes
Based on the calculations Iâve been browsing through, they had âŹ9m in cash in December. This should be enough until the autumn, but they wonât let it run completely dry. I would bet on a share issue still happening during H1.
3 Likes
In fact, if consolidation is already well underway (referring to those LinkedIn posts as well), and Aiforia is among the few leaders / perhaps even the most convincing of those not yet acquired, why couldnât an acquisition happen much sooner than I anticipated?
Are there any milestones Aiforia needs to achieve first?
Are some âproofsâ via revenue needed first, or is it enough that the models are good, EU-approved, and theyâve been able to secure contracts extensively?
(The most suitable time to apply for FDA approvals would be only once a player has integrated Aiforia as part of a scanner/image processing/AI entity, because for now, the FDA only grants clearances for such entitiesâŠ)
6 Likes
One could imagine that a buyer expects revenue growth as well as positive cash flow. At the moment, I believe Aiforia is still an expensive acquisition target at its current valuation.
1 Like
In itself, Iâm not sure if it would matter to a large player whether the situation is a few million in losses or a few million in profit, as long as the direction is clear. I suppose they are primarily buying an AI model that can be integrated into their own product to ensure the competitiveness of that product (e.g., a scanner). Jukka has repeatedly said in interviews that AI is ultimately the âcarrotâ that brings the benefit and what everyone is interested in, which could create that competitive advantage.
Revenue in itself builds credibility; the product is, in a way, more validated, more tested, and in practice probably better known for a company with high sales.
Fortunately, Aiforia is starting to have quite good references on the clinical side, even though clinical revenue has only just started moving!
Well, if you value it in relation to revenue/profitâwhich doesnât existâthen certainly. If, on the other hand, you consider that someone wants those AI models, then the market cap is 15 times cheaper than the entity with fewer models that was just acquired. By buying early, one could still get a good AI at a reasonable price; a profitable company in a few years will already be more expensive 
12 Likes
At the extraordinary general meeting (EGM) on Tuesday, May 12, the board will be authorized to carry out a share issue of a maximum of 5 million shares. At the current share price, the subscription price would likely be around âŹ1.7â1.8 per share, and the total number of shares would increase from 33.6m â 38.6m. Analysts (Antit) are still expecting one more issue of approximately 6m shares after this. We shall see whether that second issue will be needed or not.
In any case, this first issue should easily suffice for a year. The CEO also mentioned in the H2 info session that if the path is clear for strong growth, he sees no problem in securing additional financing. He also noted that it is possible to slow down growth and focus on the bottom line if the situation warrants it.
Hopefully, the participants in the upcoming issue will be more committed compared to those in December and wonât immediately dump the new shares onto the market (laitaan).
6 Likes
So is this then a roughly 14% dilution for the retail investorâŠ? Since one ends up staying on the sidelines during the offering anywayâŠ
I personally suspected that Aiforia would be acquired once EBITDA turns positive, and at the very latest when cash flow becomes positive, but if thereâs this much rustling in the reeds, it could happen even sooner.
3 Likes
Some big fish will surely buy this at some point, but probably not just yet, as insiders have only recently been buying. In my opinion, it would also be better to develop the company further and get more references and AI models â better valuation. Iâd also rather keep this on the Helsinki Stock Exchange instead of always selling everything away immediately
6 Likes
Well, the shareholder base itself is partly problematic here, as they blocked a share issue that was essential for the growth story.
5 Likes
TÀmÀ on kolmannen osapuolen analyysi, eikÀ vÀlttÀmÀttÀ vastaa Inderesin nÀkemystÀ tai arvoja.
17 Likes
Itâs easy to get excited about these M&A deals, and for good reason.
After all, itâs potentially a way to get your money back from âHesuliâ (Helsinki Stock Exchange) micro-caps, whose price development is steadily heading south (northeast in sarcasm).
However, they actually happen quite rarely, even if in Aiforiaâs case, the probabilities could be considered better than average.
Anyway, it seems PathAI has sold a large chunk of its business (lab services), and itâs not clear to an outsider what the remainder ultimately consists of, but unlikely to be entirely AI-based pathology. But I have no inside info.
The multiples (incl. earnouts) end up being 26-35x revenue.
Aiforia has an EV/Sales of 18.3 (2025) and 12.4 (2026).
As you can see, the multiples of a small growth company are heavily affected by whether that revenue growth materializes as imagined or not.
So PathAI has indeed fetched a quite decent price, assuming the revenue includes more than just the specific parts that were wanted for purchase.
**Last week, Roche announced the acquisition of PathAI for up to 1.05bn ( 750m upfront, 300m in earnouts), to be integrated into its Diagnostics division.** PathAI is privately held, and few valuation details are provided in connection with the deal. PathAI divested its lab services business to Quest Diagnostics for 100m in June 2024. Post-divestment, this could put PathAIâs FY25 sales at a range of $ 30-40m, implying a deal valuation of 26-35x sales (incl. earnouts). At Friday close, Aiforia traded at 18.3x EV/S FY25 and 12.4x EV/S FY26 (eNuW).
A strong catalyst for the market. Significant M&A moves from large healthtech players typically signal that a new technology has reached commercial viability at scale. The hefty premium paid here indicates that current revenue levels do not reflect the long-term potential of AI in oncology diagnostics. Consolidation is picking up pace, something we flagged as a strong possibility in our initiation note from October.
12 Likes
Here is Rocheâs own press release regarding the PathAI acquisition, detailing the rationale behind what they wanted to buy and why.
The arguments could be copied if someone wanted to acquire Aiforia.
However, even though peers for Bittiumâs medical business, for example, were sold at good prices, Bittiumâs medical division just continues to stagnate within the group, without growth and with withered profitability.
âBig Pharmaâ is not necessarily a good investment strategy, even if it might serve as a mental lifebuoy for someone over-invested in Helsinki-listed medical stocksâŠ
This acquisition strengthens Rocheâs position in Digital Pathology, which is transforming extensive manual workflows into fully automated, AI-driven processes and insights. Digital pathology enables the creation of high-resolution digital images from physical tissue on slides, allowing pathologists to use AI tools to facilitate diagnostic workflows and provide patients with faster results.
âDigital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens,â said Matt Sause, CEO of Roche Diagnostics. âBringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide.â
Andy Beck, CEO and Co-Founder of PathAI, adds: âJoining forces with Roche marks a new era for PathAI, enabling us to realise our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed. Rocheâs global infrastructure and expertise will bring our digital diagnostics technology to patients worldwide.â
PathAIâs AISight IMS software interface is efficient and user-friendly, seamlessly integrating advanced analysis and workflow capabilities within the digital pathology laboratory. In the rapidly growing pathology market, Roche intends to scale this solution globally.
In addition, the expanded capabilities strengthen Rocheâs competitiveness in precision medicine by enhancing its biopharma services. PathAIâs strength in AI-driven solutions, including clinical trial support and translational research, will complement Rocheâs deep expertise in companion diagnostics. Combining these capabilities will foster the discovery of new biomarkers, potential drug targets and novel diagnostic tools, increasing the value Roche can bring to biopharma companies
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
8 Likes